LIVIVO - Search results -

Search results

Result 1 - 10 of total 115

Search options

Article ; Online: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease with Frequent Cerebellitis.

Ishikura, Teruyuki / Okuno, Tatsusada / Takahashi, Toshiyuki / Mochizuki, Hideki

2022 Volume 61, Issue 23, Page(s) 3629–3630

MeSH term(s)	Humans ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies
Chemical Substances	Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies
Language	English
Publishing date	2022-05-14
Publishing country	Japan
Document type	Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.9446-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pore Formation and Shape Control Simulation of Lotus Aluminum by the Phase-Field Method.

Takahashi, Kei / Sasajima, Yasushi / Ikeda, Teruyuki

ACS omega

2022 Volume 7, Issue 17, Page(s) 14985–14993

Abstract: We have simulated pore formation and shape control of lotus aluminum by the phase-field method. The simulated material, lotus aluminum, contains anisotropic internal pores, and it is produced by the continuous casting method in a hydrogen atmosphere. ... ...

Abstract	We have simulated pore formation and shape control of lotus aluminum by the phase-field method. The simulated material, lotus aluminum, contains anisotropic internal pores, and it is produced by the continuous casting method in a hydrogen atmosphere. Since it is known experimentally that the pore shape of lotus aluminum changes with the pull-out speed, the simulation varied the movement speed of the temperature gradient zone (equivalent to the pull-out speed in the continuous casting method) by proportional differential (PD) control with the pore width as the target value. As a result, a simple PD control ensured the pores closed during the growth process. To keep the pore growth linear, we found that a lower limit of the interface temperature should be set and the temperature gradient zone should be stopped below this lower limit. However, a problem occurred in the pore shape. To mitigate necking of the pore, PD control was done only when the pore width became larger than the target value under the conditions such that the pore expanded easily (i.e., the pull-out movement was stopped for a certain time immediately after nucleation and the initial speed of the temperature gradient zone was decreased). Then, we found the best condition to achieve linear pore growth without necking. Under the same condition, we simulated multiple pore growths by allowing multiple nucleations. As a result, we observed that although the shape control was applied only to a certain single pore, the other pores also grew linearly if the timing of their nucleation was close to that of the target pore.
Language	English
Publishing date	2022-04-19
Publishing country	United States
Document type	Journal Article
ISSN	2470-1343
ISSN (online)	2470-1343
DOI	10.1021/acsomega.2c00733
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Multijurisdictional Outbreak of Enterohemorrhagic

Sato, Ryosuke / Yahata, Yuichiro / Taira, Hiroyuki / Saito, Tetsuya / Ishii, Teruyuki / Yamazaki, Satoru / Yamamoto, Kazunari / Kikuchi, Ryoko / Izumiya, Hidemasa / Iyoda, Sunao / Ohnishi, Makoto / Takahashi, Yoshiki

Foodborne pathogens and disease

2022 Volume 19, Issue 6, Page(s) 400–407

Abstract: ... ...

Abstract	Enterohemorrhagic
MeSH term(s)	Case-Control Studies ; Disease Outbreaks ; Enterohemorrhagic Escherichia coli ; Escherichia coli Infections/epidemiology ; Escherichia coli O157 ; Female ; Humans ; Japan/epidemiology ; Male ; Meat
Language	English
Publishing date	2022-05-17
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2148479-X
ISSN	1556-7125 ; 1535-3141
ISSN (online)	1556-7125
ISSN	1535-3141
DOI	10.1089/fpd.2021.0083
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 7517: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).

Tanaka, Atsushi / Okada, Yosuke / Torimoto, Keiichi / Kamei, Nozomu / Hirai, Hiroyuki / Kono, Teruyuki / Sugimoto, Kazuhiro / Teragawa, Hiroki / Taguchi, Isao / Maruhashi, Tatsuya / Sonoda, Satomi / Kurozumi, Akira / Inagaki, Saori / Oshita, Chikage / Hisauchi, Itaru / Takahashi, Kanae / Higashi, Yukihito / Shimabukuro, Michio / Node, Koichi

Diabetes & metabolism

2023 Volume 49, Issue 4, Page(s) 101447

MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Hypoglycemic Agents/therapeutic use ; Glucosides/therapeutic use ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Blood Glucose
Chemical Substances	ipragliflozin (3N2N8OOR7X) ; Hypoglycemic Agents ; Glucosides ; Blood Glucose
Language	English
Publishing date	2023-04-26
Publishing country	France
Document type	Randomized Controlled Trial ; Letter
ZDB-ID	1315751-6
ISSN	1878-1780 ; 1262-3636 ; 0338-1684
ISSN (online)	1878-1780
ISSN	1262-3636 ; 0338-1684
DOI	10.1016/j.diabet.2023.101447
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1267: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical and quantitative analysis of patients with crowned dens syndrome.

Takahashi, Teruyuki / Tamura, Masato / Takasu, Toshiaki / Kamei, Satoshi

Journal of the neurological sciences

2017 Volume 376, Page(s) 52–59

Abstract: Background: Crowned dens syndrome (CDS) is a radioclinical entity defined by calcium deposition on the transverse ligament of atlas (TLA). In this study, the novel semi-quantitative diagnostic criteria for CDS to evaluate the degree of calcification on ... ...

Abstract	Background: Crowned dens syndrome (CDS) is a radioclinical entity defined by calcium deposition on the transverse ligament of atlas (TLA). In this study, the novel semi-quantitative diagnostic criteria for CDS to evaluate the degree of calcification on TLA by cervical CT are proposed. Method: From January 2010 to September 2014, 35 patients who were diagnosed with CDS by cervical CT were adopted as subjects in this study. Based on novel criteria, calcium deposition on TLA was classified into "Stage" and "Grade", to make a score, which was evaluated semi-quantitatively. The correlation between calcification score and CRP level or pain score, and the effects of treatments, such as NSAIDs and corticosteroids, were statistically analyzed. Results: The total calcification score from added "Stage" and "Grade" scores demonstrated a significantly strong and linear correlation with CRP level (R Conclusion: The degree of calcification on TLA evaluated by the novel semi-quantitative criteria significantly correlated with CRP level. In the treatment of CDS, it is recommended that a low dosage (15-30mg) of corticosteroids be used as first-line drugs rather than conventional NSAID therapy. Additionally, it is also recommended to gradually decrease the dosage of corticosteroids.
Language	English
Publishing date	2017-05-15
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	80160-4
ISSN	1878-5883 ; 0022-510X ; 0374-8642
ISSN (online)	1878-5883
ISSN	0022-510X ; 0374-8642
DOI	10.1016/j.jns.2017.02.050
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 308: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Outcomes of regional-based newborn hearing screening for 35,461 newborns for 5 years in Akita, Japan.

Sato, Teruyuki / Nakazawa, Misao / Takahashi, Shin / Mizuno, Tomomi / Ishikawa, Kazuo / Yamada, Takechiyo

International journal of pediatric otorhinolaryngology

2020 Volume 131, Page(s) 109870

Abstract: Objectives: Newborn hearing screening (NHS) has been actively performed since 2001 in Akita, Japan. The NHS coverage rate has increased yearly, and performance has been consistently >90% since 2012. The purpose of this study was to summarize NHS ... ...

Abstract	Objectives: Newborn hearing screening (NHS) has been actively performed since 2001 in Akita, Japan. The NHS coverage rate has increased yearly, and performance has been consistently >90% since 2012. The purpose of this study was to summarize NHS outcomes in the Akita prefecture of Japan and to obtain new insights for from our summarized data for the future. Methods: A total of 35,461 newborns in hospitals and clinics where hearing screening was performed in Akita from 2012 to 2016 were included. The outcome data of NHS were collected for analysis. Results: The overall screening coverage rate for hearing loss was 94.7%. Of the screened infants, 0.53% received a referral on the 2-stage automated auditory brainstem response (ABR), and 80.4% of referred infants had a check-up at the hospital to receive a diagnostic hearing examination. Finally, the prevalence of bilateral congenital hearing loss was 0.14%, that of bilateral moderate to profound hearing loss was 0.12%, and that of unilateral congenital hearing loss was 0.10%. Furthermore, the average consultation period in infants with risk factors was significantly later than that in infants without risk factors (p = 0.0015). Follow-up for infants diagnosed with normal hearing after diagnostic hearing examination revealed that 4.7% suffered bilateral moderate to profound hearing loss later. This percentage is significantly higher than that of the general group (p < 0.001). Conclusion: The prevalence of bilateral congenital hearing loss was 0.14% in Akita and 0.12% of infants were diagnosed with bilateral moderate to severe hearing loss. Medical personnel should be enlightened regarding the importance of performing hearing diagnostic examinations until 3 months of age. Even if infants were diagnosed with normal hearing after a diagnostic examination, we strongly suggest continuing follow-up until they are able to perform pure tone audiometry with accuracy.
MeSH term(s)	Audiometry, Pure-Tone ; Evoked Potentials, Auditory, Brain Stem ; Female ; Hearing Loss, Bilateral/congenital ; Hearing Loss, Bilateral/diagnosis ; Hearing Loss, Bilateral/epidemiology ; Hearing Loss, Unilateral/congenital ; Hearing Loss, Unilateral/diagnosis ; Hearing Loss, Unilateral/epidemiology ; Humans ; Infant, Newborn ; Japan ; Male ; Neonatal Screening ; Referral and Consultation ; Risk Factors
Language	English
Publishing date	2020-01-10
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	754501-0
ISSN	1872-8464 ; 0165-5876
ISSN (online)	1872-8464
ISSN	0165-5876
DOI	10.1016/j.ijporl.2020.109870
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1507: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 134: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cerebral Small Vessel Disease Burden for Bleeding Risk during Antithrombotic Therapy: Bleeding with Antithrombotic Therapy 2 Study.

Tanaka, Kanta / Miwa, Kaori / Koga, Masatoshi / Yoshimura, Sohei / Kamiyama, Kenji / Yagita, Yoshiki / Nagakane, Yoshinari / Hoshino, Haruhiko / Terasaki, Tadashi / Okada, Yasushi / Yakushiji, Yusuke / Takahashi, Shinichi / Ueda, Toshihiro / Hasegawa, Yasuhiro / Shiozawa, Masayuki / Sasaki, Makoto / Kudo, Kohsuke / Tanaka, Jun / Nishihara, Masashi /

Yamaguchi, Yoshitaka / Fujita, Kyohei / Honda, Yuko / Kawano, Hiroyuki / Ide, Toshihiro / Yoshimoto, Takeshi / Ihara, Masafumi / Hirano, Teruyuki / Toyoda, Kazunori

Annals of neurology

2024 Volume 95, Issue 4, Page(s) 774–787

Abstract: Objective: This study was undertaken to determine the excess risk of antithrombotic-related bleeding due to cerebral small vessel disease (SVD) burden.: Methods: In this observational, prospective cohort study, patients with cerebrovascular or ... ...

Abstract	Objective: This study was undertaken to determine the excess risk of antithrombotic-related bleeding due to cerebral small vessel disease (SVD) burden. Methods: In this observational, prospective cohort study, patients with cerebrovascular or cardiovascular diseases taking oral antithrombotic agents were enrolled from 52 hospitals across Japan between 2016 and 2019. Baseline multimodal magnetic resonance imaging acquired under prespecified conditions was assessed by a central diagnostic radiology committee to calculate total SVD score. The primary outcome was major bleeding. Secondary outcomes included bleeding at each site and ischemic events. Results: Of the analyzed 5,250 patients (1,736 women; median age = 73 years, 9,933 patient-years of follow-up), antiplatelets and anticoagulants were administered at baseline in 3,948 and 1,565, respectively. Median SVD score was 2 (interquartile range = 1-3). Incidence rate of major bleeding was 0.39 (per 100 patinet-years) in score 0, 0.56 in score 1, 0.91 in score 2, 1.35 in score 3, and 2.24 in score 4 (adjusted hazard ratio [aHR] for score 4 vs 0 = 5.47, 95% confidence interval [CI] = 2.26-13.23), that of intracranial hemorrhage was 0.11, 0.33, 0.58, 0.99, and 1.06, respectively (aHR = 9.29, 95% CI = 1.99-43.35), and that of ischemic event was 1.82, 2.27, 3.04, 3.91, and 4.07, respectively (aHR = 1.76, 95% CI = 1.08-2.86). In addition, extracranial major bleeding (aHR = 3.43, 95% CI = 1.13-10.38) and gastrointestinal bleeding (aHR = 2.54, 95% CI = 1.02-6.35) significantly increased in SVD score 4 compared to score 0. Interpretation: Total SVD score was predictive for intracranial hemorrhage and probably for extracranial bleeding, suggesting the broader clinical relevance of cerebral SVD as a marker for safe implementation of antithrombotic therapy. ANN NEUROL 2024;95:774-787.
MeSH term(s)	Aged ; Female ; Humans ; Anticoagulants ; Cerebral Small Vessel Diseases/epidemiology ; Fibrinolytic Agents/adverse effects ; Hemorrhage ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/epidemiology ; Prospective Studies ; Stroke/epidemiology ; Male
Chemical Substances	Anticoagulants ; Fibrinolytic Agents
Language	English
Publishing date	2024-01-18
Publishing country	United States
Document type	Observational Study ; Journal Article
ZDB-ID	80362-5
ISSN	1531-8249 ; 0364-5134
ISSN (online)	1531-8249
ISSN	0364-5134
DOI	10.1002/ana.26868
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1370: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 478: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CDKL5 deficiency causes epileptic seizures independent of cellular mosaicism.

Takahashi, Satoru / Takeguchi, Ryo / Tanaka, Ryosuke / Fukuoka, Masataka / Koike, Takayoshi / Ohtani, Hideyuki / Inoue, Kenji / Fukuda, Mitsumasa / Kurahashi, Hirokazu / Nakamura, Kazuyuki / Tominaga, Koji / Matsubayashi, Tomoko / Itoh, Masayuki / Tanaka, Teruyuki

Journal of the neurological sciences

2022 Volume 443, Page(s) 120498

Abstract: Objective: In a study using a mouse model of CDKL5 deficiency disorder (CDD), seizures are specific to female mice heterozygous for Cdkl5 mutations and not observed in hemizygous knockout males or homozygous knockout females. The aim of this study was ... ...

Abstract	Objective: In a study using a mouse model of CDKL5 deficiency disorder (CDD), seizures are specific to female mice heterozygous for Cdkl5 mutations and not observed in hemizygous knockout males or homozygous knockout females. The aim of this study was to examine whether the clinical phenotype of patients with CDD can be impacted by the type of genetic variant. Methods: Eleven CDD patients (six females and five males) were included in this study. The molecular diagnosis of hemizygous male patients was performed using digital PCR and their clinical phenotypes were compared with those of patients with mosaic or heterozygous CDKL5 variants. The severity of clinical phenotypes was graded by using CDKL5 Developmental Score and the adapted version of the CDKL5 Clinical Severity Assessment. The effect of cellular mosaicism on the severity of CDD was studied by comparing the clinical characteristics and comorbidities between individuals with hemizygous and mosaic or heterozygous CDKL5 variants. Results: One of the five male patients was mosaic for the CDKL5 variant. All patients developed seizures irrespective of their genetic status of the pathogenic variant. However, cellular mosaicism of CDKL5 deficiency was associated with lesser severity of other comorbidities such as feeding, respiratory, and visual functional impairments. Significance: This study provided evidence that cellular mosaicism of CDKL5 deficiency was not necessarily required for developing epilepsy. CDD patients not only exhibited clinical features of epilepsy but also exhibited the developmental consequences arising directly from the effect of the CDKL5 pathogenic variant.
MeSH term(s)	Female ; Male ; Humans ; Mosaicism ; Seizures/genetics ; Spasms, Infantile/genetics ; Epilepsy ; Protein Serine-Threonine Kinases/genetics
Chemical Substances	CDKL5 protein, human (EC 2.7.11.22) ; Protein Serine-Threonine Kinases (EC 2.7.11.1)
Language	English
Publishing date	2022-11-16
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80160-4
ISSN	1878-5883 ; 0022-510X ; 0374-8642
ISSN (online)	1878-5883
ISSN	0022-510X ; 0374-8642
DOI	10.1016/j.jns.2022.120498
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 308: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS.

Science advances

2023 Volume 9, Issue 47, Page(s) eadg3193

Abstract: Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone-collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in ... ...

Abstract	Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone-collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.
MeSH term(s)	Animals ; Humans ; Mice ; Actins ; Amyotrophic Lateral Sclerosis/genetics ; Amyotrophic Lateral Sclerosis/pathology ; Antibodies ; Mice, Transgenic ; Motor Neurons/metabolism ; Superoxide Dismutase/genetics ; Superoxide Dismutase/metabolism ; Superoxide Dismutase-1/genetics
Chemical Substances	Actins ; Antibodies ; Superoxide Dismutase (EC 1.15.1.1) ; Superoxide Dismutase-1 (EC 1.15.1.1) ; Rgma protein, mouse
Language	English
Publishing date	2023-11-22
Publishing country	United States
Document type	Journal Article
ZDB-ID	2810933-8
ISSN	2375-2548 ; 2375-2548
ISSN (online)	2375-2548
ISSN	2375-2548
DOI	10.1126/sciadv.adg3193
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.

Houkin, Kiyohiro / Osanai, Toshiya / Uchiyama, Shinichiro / Minematsu, Kazuo / Taguchi, Akihiko / Maruichi, Katsuhiko / Niiya, Yoshimasa / Asaoka, Katsuyuki / Kuga, Yoshihiro / Takizawa, Katsumi / Haraguchi, Koichi / Yoshimura, Shinichi / Kimura, Kazumi / Tokunaga, Koji / Aoyama, Atsuo / Ikawa, Fusao / Inenaga, Chikanori / Abe, Tatsuya / Tominaga, Atsushi /

Takahashi, Shinichi / Kudo, Kohsuke / Fujimura, Miki / Sugiyama, Taku / Ito, Masaki / Kawabori, Masahito / Hess, David C / Savitz, Sean I / Hirano, Teruyuki

JAMA neurology

2024 Volume 81, Issue 2, Page(s) 154–162

Abstract: Importance: Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow-derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ... ...

Abstract	Importance: Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow-derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. Objective: To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset. Design, setting, and participants: The Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic and clinical centers in Japan between November 15, 2017, and March 29, 2022. Inclusion criteria were age 20 years or older, presence of acute ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 8-20 at baseline), confirmed acute infarction involving the cerebral cortex and measuring more than 2 cm on the major axis (determined with diffusion-weighted magnetic resonance imaging), and a modified Rankin Scale (mRS) score of 0 or 1 before stroke onset. Data analysis was performed between May 9 and August 15, 2022. Exposure: Patients were randomly assigned to either intravenous MultiStem in 1 single unit of 1.2 billion cells or intravenous placebo within 18 to 36 hours of ischemic stroke onset. Main outcomes and measures: The primary end points were safety and excellent outcome at day 90, measured as a composite of a modified Rankin Scale (mRS) score of 1 or less, a NIHSS score of 1 or less, and a Barthel index score of 95 or greater. The secondary end points were excellent outcome at day 365, mRS score distribution at days 90 and 365, and mRS score of 0 to 1 and 0 to 2 at day 90. Statistical analysis of efficacy was performed using the Cochran-Mantel-Haenszel test. Results: This study included 206 patients (104 received MultiStem and 102 received placebo). Their mean age was 76.5 (range, 35-95) years, and more than half of patients were men (112 [54.4%]). There were no between-group differences in primary and secondary end points. The proportion of excellent outcomes at day 90 did not differ significantly between the MultiStem and placebo groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, -7.3% to 8.3%]). The frequency of adverse events was similar between treatment groups. Conclusions and relevance: In this randomized clinical trial, intravenous administration of allogeneic cell therapy within 18 to 36 hours of ischemic stroke onset was safe but did not improve short-term outcomes. Further research is needed to determine whether MultiStem therapy for ischemic stroke has a beneficial effect in patients who meet specific criteria, as indicated by the exploratory analyses in this study. Trial registration: ClinicalTrials.gov Identifier: NCT02961504.
MeSH term(s)	Adult ; Male ; Humans ; Aged ; Young Adult ; Female ; Ischemic Stroke/complications ; Brain Ischemia/complications ; Stroke/drug therapy ; Double-Blind Method ; Stem Cell Transplantation ; Hematopoietic Stem Cell Transplantation ; Treatment Outcome
Language	English
Publishing date	2024-01-16
Publishing country	United States
Document type	Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase II ; Clinical Trial, Phase III ; Journal Article
ZDB-ID	2702023-X
ISSN	2168-6157 ; 2168-6149
ISSN (online)	2168-6157
ISSN	2168-6149
DOI	10.1001/jamaneurol.2023.5200
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.191: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito